• Something wrong with this record ?

Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases

S. Giallongo, O. Lo Re, I. Resnick, M. Raffaele, M. Vinciguerra

. 2023 ; 1396 (-) : 275-298. [pub] -

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22032007

The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032007
003      
CZ-PrNML
005      
20230131150629.0
007      
ta
008      
230120s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/978-981-19-5642-3_18 $2 doi
035    __
$a (PubMed)36454473
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Giallongo, Sebastiano $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic
245    10
$a Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases / $c S. Giallongo, O. Lo Re, I. Resnick, M. Raffaele, M. Vinciguerra
520    9_
$a The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.
650    _2
$a lidé $7 D006801
650    12
$a indukované pluripotentní kmenové buňky $7 D057026
650    _2
$a editace genu $7 D000072669
650    12
$a diabetes mellitus 2. typu $x genetika $x terapie $7 D003924
650    12
$a kardiovaskulární systém $7 D002319
650    12
$a metabolické nemoci $x genetika $x terapie $7 D008659
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lo Re, Oriana $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria
700    1_
$a Resnick, Igor $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria $u Department of Hematology, Bone Marrow Transplantation and Cell Therapy of St. Marina University Hospital, Varna, Bulgaria
700    1_
$a Raffaele, Marco $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic
700    1_
$a Vinciguerra, Manlio $u Epigenetics, Metabolism and Aging Unit, Center for Translational Medicine, International Clinical Research Center, St'Anne University Hospital, Brno, Czech Republic. manliovinciguerra@gmail.com $u Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University - Varna, Varna, Bulgaria. manliovinciguerra@gmail.com $u Liverpool Centre for Cardiovascular Science (LCCS), Liverpool John Moores University (LJMU), Liverpool, United Kingdom. manliovinciguerra@gmail.com
773    0_
$w MED00008501 $t Advances in experimental medicine and biology $x 0065-2598 $g Roč. 1396, č. - (2023), s. 275-298
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36454473 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150626 $b ABA008
999    __
$a ok $b bmc $g 1891032 $s 1183342
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 1396 $c - $d 275-298 $e - $i 0065-2598 $m Advances in experimental medicine and biology $n Adv Exp Med Biol $x MED00008501
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options